Farms.com Home   News

Transparent Labeling Stressed in Beef vs Lab-Grown Meat Battle

The emergence of cell-based proteins, or lab-grown meat, has stirred dialogue within the beef industry. National Cattlemen’s Beef Association (NCBA) CEO, Colin Woodall, made it clear that the issue is not about fearing these new products, but about ensuring they adhere to the same rules as traditional meat producers. 

An inspection certificate granted by the USDA to a cell-based chicken product has been welcomed by the industry as a step in the right direction. According to Woodall, frequent inspections - the norm in the conventional meat industry - should also apply to these new products. 

The NCBA is intent on achieving transparency in labeling cell-based proteins. Suggested terms include "lab-grown", "synthetic", and "cell-cultured", aiming to prevent confusion and misleading marketing tactics. The term "slaughter-free beef", for example, could create confusion and mislead consumers. 

While NCBA is not against cell-based protein products, Woodall stresses the importance of consumer understanding and equality in the marketplace. Despite the advent of these new products, Woodall remains confident about the beef industry’s competitiveness owing to the unique taste of beef. 

He ended by reinforcing the necessity of a level playing field through consistent inspection protocols and transparent labeling. This would, he believes, allow for fair competition and ensure consumers make informed choices. 

Source : wisconsinagconnection

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.